Floatz logo

Clenbuterol

Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset

Duke UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset cohort.

Asset / SponsorPhaseRating
Alglucosidase Alfa
Erasmus Medical Center
Phase 4BBB
Cipaglucosidase Alfa
Amicus Therapeutics
Phase 3BB
Avalglucosidase Alfa
Iris Plug
Phase 4BB
at2221
Amicus Therapeutics
Phase 3B
Miglustat
Amicus Therapeutics
Phase 3B

View all 13 →

Same molecule, other indications

Clenbuterol is also rated in:

amyotrophic lateral sclerosisDormant
CCC
Indicative · Phase 2
54 / 100
View asset →
type 2 diabetes mellitusActive
CCC
Indicative · Phase 2
54 / 100
View asset →
Kennedy diseaseActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →